From patent to patient: analysing access to innovative cancer drugs.
Loading...
Embargo End Date
ICR Authors
Authors
Sharpe, E
Hoey, R
Yap, C
Workman, P
Hoey, R
Yap, C
Workman, P
Document Type
Journal Article
Date
2020-09-01
Date Accepted
2020-01-15
Abstract
Analysis of cancer drugs licensed through the European Medicines Agency (EMA) in 2000-2016 shows that the number of authorisations increased over that timeframe. The median number of licensed drugs each year rose from six for 2000-2008 to 13.5 for 2009-2016. Over 2000-2016, there were 64 drug authorisations for haematological, 15 for breast, and 12 for skin cancer, but none for oesophageal, brain, bladder, or uterine cancer. Only 6% of authorisations included a paediatric indication. The average time for a drug to progress from patent priority date to availability on the National Health Service (NHS) increased from 12.8 years for drugs first licensed in 2000-2008 to 14.0 years for those licensed in 2009-2016. There was evidence that the most innovative drugs were not being prioritised for EMA licensing and NICE approval.
Citation
Drug discovery today, 2020, 25 (9), pp. 1561 - 1568
Source Title
Publisher
ELSEVIER SCI LTD
ISSN
1359-6446
eISSN
1878-5832
Collections
Research Team
Clinical Trials & Statistics Unit